FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016989186> ?p ?o ?g. }

• W3016989186 abstract "Background Vorapaxar as an adjunct to dual antiplatelet therapy ( DAPT ) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. The pharmacodynamic effects of vorapaxar with potent P2Y 12 inhibitors as well as the impact of dropping aspirin is unexplored and represented the aim of the VORA‐PRATIC (Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With Newer Generation P2Y 12 Receptor Inhibitors Prasugrel and Ticagrelor) study. Methods and Results Post–myocardial infarction patients (n=130) on standard DAPT (aspirin+prasugrel or ticagrelor) were randomized to 1 of 3 arms: (1) triple therapy: aspirin+prasugrel/ticagrelor+vorapaxar; (2) dual therapy (drop aspirin): prasugrel/ticagrelor+vorapaxar; (3) DAPT : aspirin+prasugrel/ticagrelor. Pharmacodynamic assessments were performed at 3 time points (baseline and 7 and 30 days). Vorapaxar reduced CAT (collagen‐ADP‐TRAP)–induced platelet aggregation, a marker of platelet‐mediated global thrombogenicity (triple therapy versus DAPT at 30 days: mean difference=–27; 95% CI ,–35 to –19; P <0.001; primary end point). This effect was attenuated but still significant in the absence of aspirin (dual therapy versus DAPT at 30 days: mean difference=–15; 95% CI ,–23 to –7; P <0.001; between‐group comparisons, P <0.05). Vorapaxar abolished TRAP–induced aggregation ( P <0.001), without affecting thrombin generation and clot strength. There were no differences in markers of P2Y 12 reactivity. Markers sensitive to aspirin‐induced effects increased ( P <0.001) in the dual‐therapy arm. Conclusions In post–myocardial infarction patients treated with potent P2Y 12 inhibitors, vorapaxar reduces platelet‐driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin and without affecting markers of P2Y 12 reactivity or clot kinetics. The clinical implications of these PD observations warrant future investigation. Registration URL : https://www.clini​caltr​ials.gov . Unique identifier: NCT 02545933." @default.
• W3016989186 created "2020-04-24" @default.
• W3016989186 creator A5000539924 @default.
• W3016989186 creator A5010622922 @default.
• W3016989186 creator A5013986140 @default.
• W3016989186 creator A5015557461 @default.
• W3016989186 creator A5016139987 @default.
• W3016989186 creator A5020523437 @default.
• W3016989186 creator A5024294469 @default.
• W3016989186 creator A5028373176 @default.
• W3016989186 creator A5028730426 @default.
• W3016989186 creator A5033687434 @default.
• W3016989186 creator A5033895446 @default.
• W3016989186 creator A5037680285 @default.
• W3016989186 creator A5039226707 @default.
• W3016989186 creator A5040418600 @default.
• W3016989186 creator A5044691392 @default.
• W3016989186 creator A5052874513 @default.
• W3016989186 creator A5060452923 @default.
• W3016989186 creator A5061638267 @default.
• W3016989186 creator A5064454518 @default.
• W3016989186 creator A5069403767 @default.
• W3016989186 creator A5076855633 @default.
• W3016989186 creator A5083495465 @default.
• W3016989186 creator A5091537864 @default.
• W3016989186 date "2020-04-21" @default.
• W3016989186 modified "2023-10-11" @default.
• W3016989186 title "Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y ₁₂ Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study" @default.
• W3016989186 cites W1575456191 @default.
• W3016989186 cites W1825734667 @default.
• W3016989186 cites W1907663636 @default.
• W3016989186 cites W1930503019 @default.
• W3016989186 cites W1974709342 @default.
• W3016989186 cites W1986266381 @default.
• W3016989186 cites W2018383335 @default.
• W3016989186 cites W2058217708 @default.
• W3016989186 cites W2073737948 @default.
• W3016989186 cites W2080766382 @default.
• W3016989186 cites W2105735830 @default.
• W3016989186 cites W2122779695 @default.
• W3016989186 cites W2134322421 @default.
• W3016989186 cites W2142021807 @default.
• W3016989186 cites W2143342727 @default.
• W3016989186 cites W2156725039 @default.
• W3016989186 cites W2158910198 @default.
• W3016989186 cites W2166196321 @default.
• W3016989186 cites W2166268102 @default.
• W3016989186 cites W2182042869 @default.
• W3016989186 cites W2284409753 @default.
• W3016989186 cites W2510902864 @default.
• W3016989186 cites W2763383713 @default.
• W3016989186 cites W2795076463 @default.
• W3016989186 cites W2809722890 @default.
• W3016989186 cites W2887786226 @default.
• W3016989186 cites W2902635828 @default.
• W3016989186 cites W2970252877 @default.
• W3016989186 cites W2976166882 @default.
• W3016989186 cites W2980596005 @default.
• W3016989186 cites W3005964164 @default.
• W3016989186 doi "https://doi.org/10.1161/jaha.120.015865" @default.
• W3016989186 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7428520" @default.
• W3016989186 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32306797" @default.
• W3016989186 hasPublicationYear "2020" @default.
• W3016989186 type Work @default.
• W3016989186 sameAs 3016989186 @default.
• W3016989186 citedByCount "16" @default.
• W3016989186 countsByYear W30169891862020 @default.
• W3016989186 countsByYear W30169891862021 @default.
• W3016989186 countsByYear W30169891862022 @default.
• W3016989186 countsByYear W30169891862023 @default.
• W3016989186 crossrefType "journal-article" @default.
• W3016989186 hasAuthorship W3016989186A5000539924 @default.
• W3016989186 hasAuthorship W3016989186A5010622922 @default.
• W3016989186 hasAuthorship W3016989186A5013986140 @default.
• W3016989186 hasAuthorship W3016989186A5015557461 @default.
• W3016989186 hasAuthorship W3016989186A5016139987 @default.
• W3016989186 hasAuthorship W3016989186A5020523437 @default.
• W3016989186 hasAuthorship W3016989186A5024294469 @default.
• W3016989186 hasAuthorship W3016989186A5028373176 @default.
• W3016989186 hasAuthorship W3016989186A5028730426 @default.
• W3016989186 hasAuthorship W3016989186A5033687434 @default.
• W3016989186 hasAuthorship W3016989186A5033895446 @default.
• W3016989186 hasAuthorship W3016989186A5037680285 @default.
• W3016989186 hasAuthorship W3016989186A5039226707 @default.
• W3016989186 hasAuthorship W3016989186A5040418600 @default.
• W3016989186 hasAuthorship W3016989186A5044691392 @default.
• W3016989186 hasAuthorship W3016989186A5052874513 @default.
• W3016989186 hasAuthorship W3016989186A5060452923 @default.
• W3016989186 hasAuthorship W3016989186A5061638267 @default.
• W3016989186 hasAuthorship W3016989186A5064454518 @default.
• W3016989186 hasAuthorship W3016989186A5069403767 @default.
• W3016989186 hasAuthorship W3016989186A5076855633 @default.
• W3016989186 hasAuthorship W3016989186A5083495465 @default.
• W3016989186 hasAuthorship W3016989186A5091537864 @default.
• W3016989186 hasBestOaLocation W30169891861 @default.
• W3016989186 hasConcept C111113717 @default.
• W3016989186 hasConcept C112705442 @default.
• W3016989186 hasConcept C126322002 @default.
• W3016989186 hasConcept C164705383 @default.
• W3016989186 hasConcept C2777028646 @default.

• next